Xeloda (capecitabine) dosing, indications, interactions, adverse effects, and more (original) (raw)

All Interactions Sort By:

Contraindicated (0)

Serious (21)

• adenovirus types 4 and 7 live, oral
  capecitabine decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.
• axicabtagene ciloleucel
  capecitabine, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• brexucabtagene autoleucel
  capecitabine, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• cedazuridine
  cedazuridine will increase the level or effect of capecitabine by decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs.
• ciltacabtagene autoleucel
  capecitabine, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• deferiprone
  deferiprone, capecitabine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently.
• enoxaparin
  capecitabine increases effects of enoxaparin by unspecified interaction mechanism. Avoid or Use Alternate Drug. An additive risk of bleeding with enoxaparin may be seen in thrombocytopenic patients receiving antineoplastic agents like capecitabine.
• erdafitinib
  capecitabine will increase the level or effect of erdafitinib by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with strong CYP2C9 inhibitors, monitor closely for adverse reactions and consider decreasing dose accordingly. If strong CYP2C9 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities.
• etrasimod
  etrasimod, capecitabine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Risk of additive immune system effects with etrasimod has not been studied in combination with antineoplastic, immune-modulating, or noncorticosteroid immunosuppressive therapies. Avoid coadministration during and in the weeks following administration of etrasimod. .
• fexinidazole
  fexinidazole and capecitabine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
• givinostat
  capecitabine and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.
• idecabtagene vicleucel
  capecitabine, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• influenza virus vaccine quadrivalent, adjuvanted
  capecitabine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.
• influenza virus vaccine trivalent, adjuvanted
  capecitabine decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.
• lefamulin
  lefamulin and capecitabine both increase QTc interval. Avoid or Use Alternate Drug.
• lisocabtagene maraleucel
  capecitabine, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• palifermin
  palifermin increases toxicity of capecitabine by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.
• ropeginterferon alfa 2b
  ropeginterferon alfa 2b, capecitabine. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.
• siponimod
  capecitabine will increase the level or effect of siponimod by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with drugs that cause moderate CYP2C9 AND a moderate or strong CYP3A4 inhibition is not recommended. Caution if siponimod coadministered with moderate CYP2C9 inhibitors alone.
• tisagenlecleucel
  capecitabine, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.
• tofacitinib
  capecitabine, tofacitinib. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

Monitor Closely (67)

• aluminum hydroxide
  aluminum hydroxide increases levels of capecitabine by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
• antithrombin alfa
  capecitabine increases effects of antithrombin alfa by unspecified interaction mechanism. Use Caution/Monitor.
• antithrombin III
  capecitabine increases effects of antithrombin III by unspecified interaction mechanism. Use Caution/Monitor.
• argatroban
  capecitabine increases effects of argatroban by unspecified interaction mechanism. Use Caution/Monitor.
• arsenic trioxide
  capecitabine and arsenic trioxide both increase QTc interval. Use Caution/Monitor.
• bedaquiline
  capecitabine and bedaquiline both increase QTc interval. Use Caution/Monitor.
• belatacept
  belatacept and capecitabine both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.
• bivalirudin
  capecitabine increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor.
• chlorpromazine
  capecitabine and chlorpromazine both increase QTc interval. Use Caution/Monitor.
• cholera vaccine
  capecitabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.
• cisapride
  capecitabine and cisapride both decrease QTc interval. Use Caution/Monitor.
• dalteparin
  capecitabine increases effects of dalteparin by unspecified interaction mechanism. Use Caution/Monitor.
• dengue vaccine
  capecitabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.
• denosumab
  capecitabine, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.
• dexlansoprazole
  dexlansoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.
• dichlorphenamide
  dichlorphenamide and capecitabine both decrease serum potassium. Use Caution/Monitor.
• diclofenac
  capecitabine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID
• disopyramide
  capecitabine and disopyramide both increase QTc interval. Use Caution/Monitor.
• dofetilide
  capecitabine and dofetilide both increase QTc interval. Use Caution/Monitor.
• dronabinol
  capecitabine will increase the level or effect of dronabinol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Dronabinol is a CYP2C9 substrate.
• eluxadoline
  capecitabine increases levels of eluxadoline by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2C9/10 inhibitors.
• ethotoin
  capecitabine increases levels of ethotoin by unknown mechanism. Use Caution/Monitor. Based on case reports.
• fingolimod
  capecitabine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .
• fondaparinux
  capecitabine increases effects of fondaparinux by unspecified interaction mechanism. Use Caution/Monitor.
• fosphenytoin
  capecitabine increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor. Based on case reports.
• fostemsavir
  capecitabine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
• gilteritinib
  gilteritinib and capecitabine both increase QTc interval. Use Caution/Monitor.
• glyburide
  capecitabine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.
• goserelin
  capecitabine and goserelin both increase QTc interval. Use Caution/Monitor.
• haloperidol
  capecitabine and haloperidol both increase QTc interval. Use Caution/Monitor.
• heparin
  capecitabine increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor.
• histrelin
  capecitabine and histrelin both increase QTc interval. Use Caution/Monitor.
• ibutilide
  capecitabine and ibutilide both increase QTc interval. Use Caution/Monitor.
• influenza A (H5N1) vaccine
  capecitabine decreases effects of influenza A (H5N1) vaccine by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine.
• lacosamide
  capecitabine increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
• lansoprazole
  lansoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.
• lenvatinib
  capecitabine and lenvatinib both increase QTc interval. Use Caution/Monitor.
• lesinurad (DSC)
  capecitabine will increase the level or effect of lesinurad (DSC) by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
• leucovorin
  leucovorin increases effects of capecitabine by pharmacodynamic synergism. Use Caution/Monitor.
• mavorixafor
  mavorixafor and capecitabine both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.
• meningococcal group B vaccine
  capecitabine decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.
• methadone
  capecitabine and methadone both increase QTc interval. Use Caution/Monitor.
• ofatumumab SC
  ofatumumab SC, capecitabine. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.
• olaparib
  capecitabine and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity.
• olodaterol inhaled
  capecitabine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.
• omeprazole
  omeprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.
• osilodrostat
  osilodrostat and capecitabine both increase QTc interval. Use Caution/Monitor.
• ospemifene
  capecitabine increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
• pantoprazole
  pantoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.
• phenytoin
  capecitabine increases levels of phenytoin by unknown mechanism. Use Caution/Monitor. Based on case reports.
• procainamide
  capecitabine and procainamide both increase QTc interval. Use Caution/Monitor.
• protamine
  capecitabine increases effects of protamine by unspecified interaction mechanism. Use Caution/Monitor.
• quinidine
  capecitabine and quinidine both increase QTc interval. Use Caution/Monitor.
• quinine
  capecitabine and quinine both increase QTc interval. Use Caution/Monitor.
• rabeprazole
  rabeprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.
• selpercatinib
  capecitabine and selpercatinib both increase QTc interval. Use Caution/Monitor.
• siponimod
  siponimod and capecitabine both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.
• sipuleucel-T
  capecitabine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.
• sodium citrate/citric acid
  sodium citrate/citric acid increases levels of capecitabine by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
• terbinafine
  capecitabine will increase the level or effect of terbinafine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.
• trastuzumab
  trastuzumab, capecitabine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .
• trastuzumab deruxtecan
  trastuzumab deruxtecan, capecitabine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .
• ublituximab
  ublituximab and capecitabine both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered
• vandetanib
  capecitabine and vandetanib both increase QTc interval. Use Caution/Monitor.
• voclosporin
  capecitabine and voclosporin both increase QTc interval. Use Caution/Monitor.
• warfarin
  capecitabine will increase the level or effect of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Closely monitor INR and PT and adjust dose. Increased INR and PT can occur within a few days of initiating capecitabine.
• ziprasidone
  capecitabine and ziprasidone both increase QTc interval. Use Caution/Monitor.

Minor (6)

• esomeprazole
  esomeprazole decreases effects of capecitabine by unknown mechanism. Minor/Significance Unknown. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption. However, a randomized crossover study found esomeprazole did not affect capecitabine systemic exposure.

• food
  food decreases levels of capecitabine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Food has shown to reduce both the rate and extent of absorption of capecitabine.

• maitake
  maitake increases effects of capecitabine by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).

• taurine
  capecitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.

• vitamin A
  vitamin A, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs.

• vitamin E
  vitamin E, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs.

• adenovirus types 4 and 7 live, oral
  Serious - Use Alternative (1)capecitabine decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy.

• aluminum hydroxide
  Monitor Closely (1)aluminum hydroxide increases levels of capecitabine by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

• antithrombin alfa
  Monitor Closely (1)capecitabine increases effects of antithrombin alfa by unspecified interaction mechanism. Use Caution/Monitor.

• antithrombin III
  Monitor Closely (1)capecitabine increases effects of antithrombin III by unspecified interaction mechanism. Use Caution/Monitor.

• argatroban
  Monitor Closely (1)capecitabine increases effects of argatroban by unspecified interaction mechanism. Use Caution/Monitor.

• arsenic trioxide
  Monitor Closely (1)capecitabine and arsenic trioxide both increase QTc interval. Use Caution/Monitor.

• axicabtagene ciloleucel
  Serious - Use Alternative (1)capecitabine, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• bedaquiline
  Monitor Closely (1)capecitabine and bedaquiline both increase QTc interval. Use Caution/Monitor.

• belatacept
  Monitor Closely (1)belatacept and capecitabine both increase immunosuppressive effects; risk of infection. Use Caution/Monitor.

• bivalirudin
  Monitor Closely (1)capecitabine increases effects of bivalirudin by unspecified interaction mechanism. Use Caution/Monitor.

• brexucabtagene autoleucel
  Serious - Use Alternative (1)capecitabine, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• cedazuridine
  Serious - Use Alternative (1)cedazuridine will increase the level or effect of capecitabine by decreasing metabolism. Avoid or Use Alternate Drug. Cedazuridine, a CDA inhibitor, is used with decitabine to increase systemic exposure of decitabine. Use with other drugs metabolized by CDA may increase levels and toxicities of those drugs.

• chlorpromazine
  Monitor Closely (1)capecitabine and chlorpromazine both increase QTc interval. Use Caution/Monitor.

• cholera vaccine
  Monitor Closely (1)capecitabine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.

• ciltacabtagene autoleucel
  Serious - Use Alternative (1)capecitabine, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• cisapride
  Monitor Closely (1)capecitabine and cisapride both decrease QTc interval. Use Caution/Monitor.

• dalteparin
  Monitor Closely (1)capecitabine increases effects of dalteparin by unspecified interaction mechanism. Use Caution/Monitor.

• deferiprone
  Serious - Use Alternative (1)deferiprone, capecitabine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently.

• dengue vaccine
  Monitor Closely (1)capecitabine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine.

• denosumab
  Monitor Closely (1)capecitabine, denosumab. Other (see comment). Use Caution/Monitor. Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.

• dexlansoprazole
  Monitor Closely (1)dexlansoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.

• dichlorphenamide
  Monitor Closely (1)dichlorphenamide and capecitabine both decrease serum potassium. Use Caution/Monitor.

• diclofenac
  Monitor Closely (1)capecitabine will increase the level or effect of diclofenac by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Do not exceed diclofenac dose of 50 mg BID

• disopyramide
  Monitor Closely (1)capecitabine and disopyramide both increase QTc interval. Use Caution/Monitor.

• dofetilide
  Monitor Closely (1)capecitabine and dofetilide both increase QTc interval. Use Caution/Monitor.

• dronabinol
  Monitor Closely (1)capecitabine will increase the level or effect of dronabinol by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Dronabinol is a CYP2C9 substrate.

• eluxadoline
  Monitor Closely (1)capecitabine increases levels of eluxadoline by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2C9/10 inhibitors.

• enoxaparin
  Serious - Use Alternative (1)capecitabine increases effects of enoxaparin by unspecified interaction mechanism. Avoid or Use Alternate Drug. An additive risk of bleeding with enoxaparin may be seen in thrombocytopenic patients receiving antineoplastic agents like capecitabine.

• erdafitinib
  Serious - Use Alternative (1)capecitabine will increase the level or effect of erdafitinib by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with strong CYP2C9 inhibitors, monitor closely for adverse reactions and consider decreasing dose accordingly. If strong CYP2C9 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities.

• esomeprazole
  Minor (1)esomeprazole decreases effects of capecitabine by unknown mechanism. Minor/Significance Unknown. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption. However, a randomized crossover study found esomeprazole did not affect capecitabine systemic exposure.

• ethotoin
  Monitor Closely (1)capecitabine increases levels of ethotoin by unknown mechanism. Use Caution/Monitor. Based on case reports.

• etrasimod
  Serious - Use Alternative (1)etrasimod, capecitabine. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Risk of additive immune system effects with etrasimod has not been studied in combination with antineoplastic, immune-modulating, or noncorticosteroid immunosuppressive therapies. Avoid coadministration during and in the weeks following administration of etrasimod. .

• fexinidazole
  Serious - Use Alternative (1)fexinidazole and capecitabine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

• fingolimod
  Monitor Closely (1)capecitabine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .

• fondaparinux
  Monitor Closely (1)capecitabine increases effects of fondaparinux by unspecified interaction mechanism. Use Caution/Monitor.

• food
  Minor (1)food decreases levels of capecitabine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Food has shown to reduce both the rate and extent of absorption of capecitabine.

• fosphenytoin
  Monitor Closely (1)capecitabine increases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor. Based on case reports.

• fostemsavir
  Monitor Closely (1)capecitabine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

• gilteritinib
  Monitor Closely (1)gilteritinib and capecitabine both increase QTc interval. Use Caution/Monitor.

• givinostat
  Serious - Use Alternative (1)capecitabine and givinostat both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.

• glyburide
  Monitor Closely (1)capecitabine increases levels of glyburide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Strong CYP2C9 inhibitors may decrease glyburide metabolism.

• goserelin
  Monitor Closely (1)capecitabine and goserelin both increase QTc interval. Use Caution/Monitor.

• haloperidol
  Monitor Closely (1)capecitabine and haloperidol both increase QTc interval. Use Caution/Monitor.

• heparin
  Monitor Closely (1)capecitabine increases effects of heparin by unspecified interaction mechanism. Use Caution/Monitor.

• histrelin
  Monitor Closely (1)capecitabine and histrelin both increase QTc interval. Use Caution/Monitor.

• ibutilide
  Monitor Closely (1)capecitabine and ibutilide both increase QTc interval. Use Caution/Monitor.

• idecabtagene vicleucel
  Serious - Use Alternative (1)capecitabine, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• influenza A (H5N1) vaccine
  Monitor Closely (1)capecitabine decreases effects of influenza A (H5N1) vaccine by Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine.

• influenza virus vaccine quadrivalent, adjuvanted
  Serious - Use Alternative (1)capecitabine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.

• influenza virus vaccine trivalent, adjuvanted
  Serious - Use Alternative (1)capecitabine decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.

• lacosamide
  Monitor Closely (1)capecitabine increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.

• lansoprazole
  Monitor Closely (1)lansoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.

• lefamulin
  Serious - Use Alternative (1)lefamulin and capecitabine both increase QTc interval. Avoid or Use Alternate Drug.

• lenvatinib
  Monitor Closely (1)capecitabine and lenvatinib both increase QTc interval. Use Caution/Monitor.

• lesinurad (DSC)
  Monitor Closely (1)capecitabine will increase the level or effect of lesinurad (DSC) by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.

• leucovorin
  Monitor Closely (1)leucovorin increases effects of capecitabine by pharmacodynamic synergism. Use Caution/Monitor.

• lisocabtagene maraleucel
  Serious - Use Alternative (1)capecitabine, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• maitake
  Minor (1)maitake increases effects of capecitabine by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).

• mavorixafor
  Monitor Closely (1)mavorixafor and capecitabine both increase QTc interval. Modify Therapy/Monitor Closely. Mavorixafor causes concentration-dependent QTc prolongation. Monitor QTc during treatment in patients with risk factors for QTc prolongation (eg, coadministered medications that increase mavorixafor exposure or other drugs with a high risk to prolong the QTc interval). Mavorixafor dose reduction or discontinuation may be required.

• meningococcal group B vaccine
  Monitor Closely (1)capecitabine decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.

• methadone
  Monitor Closely (1)capecitabine and methadone both increase QTc interval. Use Caution/Monitor.

• ofatumumab SC
  Monitor Closely (1)ofatumumab SC, capecitabine. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC.

• olaparib
  Monitor Closely (1)capecitabine and olaparib both increase pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents, may potentiate and prolongate the myelosuppressive toxicity.

• olodaterol inhaled
  Monitor Closely (1)capecitabine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.

• omeprazole
  Monitor Closely (1)omeprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.

• osilodrostat
  Monitor Closely (1)osilodrostat and capecitabine both increase QTc interval. Use Caution/Monitor.

• ospemifene
  Monitor Closely (1)capecitabine increases levels of ospemifene by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

• palifermin
  Serious - Use Alternative (1)palifermin increases toxicity of capecitabine by Other (see comment). Avoid or Use Alternate Drug. Comment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis.

• pantoprazole
  Monitor Closely (1)pantoprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.

• phenytoin
  Monitor Closely (1)capecitabine increases levels of phenytoin by unknown mechanism. Use Caution/Monitor. Based on case reports.

• procainamide
  Monitor Closely (1)capecitabine and procainamide both increase QTc interval. Use Caution/Monitor.

• protamine
  Monitor Closely (1)capecitabine increases effects of protamine by unspecified interaction mechanism. Use Caution/Monitor.

• quinidine
  Monitor Closely (1)capecitabine and quinidine both increase QTc interval. Use Caution/Monitor.

• quinine
  Monitor Closely (1)capecitabine and quinine both increase QTc interval. Use Caution/Monitor.

• rabeprazole
  Monitor Closely (1)rabeprazole decreases effects of capecitabine by unknown mechanism. Use Caution/Monitor. Retrospective data suggest elevated gastric pH caused by PPI use may impair capecitabine tablet dissolution and/or reduce absorption.

• ropeginterferon alfa 2b
  Serious - Use Alternative (1)ropeginterferon alfa 2b, capecitabine. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression.

• selpercatinib
  Monitor Closely (1)capecitabine and selpercatinib both increase QTc interval. Use Caution/Monitor.

• siponimod
  Monitor Closely (1)siponimod and capecitabine both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.Serious - Use Alternative (1)capecitabine will increase the level or effect of siponimod by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with drugs that cause moderate CYP2C9 AND a moderate or strong CYP3A4 inhibition is not recommended. Caution if siponimod coadministered with moderate CYP2C9 inhibitors alone.

• sipuleucel-T
  Monitor Closely (1)capecitabine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.

• sodium citrate/citric acid
  Monitor Closely (1)sodium citrate/citric acid increases levels of capecitabine by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

• taurine
  Minor (1)capecitabine decreases levels of taurine by unspecified interaction mechanism. Minor/Significance Unknown.

• terbinafine
  Monitor Closely (1)capecitabine will increase the level or effect of terbinafine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

• tisagenlecleucel
  Serious - Use Alternative (1)capecitabine, tisagenlecleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• tofacitinib
  Serious - Use Alternative (1)capecitabine, tofacitinib. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.

• trastuzumab
  Monitor Closely (1)trastuzumab, capecitabine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .

• trastuzumab deruxtecan
  Monitor Closely (1)trastuzumab deruxtecan, capecitabine. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .

• ublituximab
  Monitor Closely (1)ublituximab and capecitabine both increase immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered

• vandetanib
  Monitor Closely (1)capecitabine and vandetanib both increase QTc interval. Use Caution/Monitor.

• vitamin A
  Minor (1)vitamin A, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs.

• vitamin E
  Minor (1)vitamin E, capecitabine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs.

• voclosporin
  Monitor Closely (1)capecitabine and voclosporin both increase QTc interval. Use Caution/Monitor.

• warfarin
  Monitor Closely (1)capecitabine will increase the level or effect of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Closely monitor INR and PT and adjust dose. Increased INR and PT can occur within a few days of initiating capecitabine.

• ziprasidone
  Monitor Closely (1)capecitabine and ziprasidone both increase QTc interval. Use Caution/Monitor.